Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer’s disease mice model

Peng Jin1,2, Jin-A Kim1,2, Dong-Young Choi4, Young-Jung Lee5, Heon Sang Jung2,3 and Jin Tae Hong1,2*

Abstract

Background: Alzheimer’s disease (AD) is pathologically characterized by excessive accumulation of amyloid-beta (Aβ) fibrils within the brain and activation of astrocytes and microglial cells. In this study, we examined anti-inflammatory and anti-amyloidogenic effects of 2,4-bis(p-hydroxyphenyl)-2-butenal (HPB242), an anti-inflammatory compound produced by the tyrosine-fructose Maillard reaction.

Methods: 12-month-old Tg2576 mice were treated with HPB242 (5 mg/kg) for 1 month and then cognitive function was assessed by the Morris water maze test and passive avoidance test. In addition, western blot analysis, Gel electromobility shift assay, immunostaining, immunofluorescence staining, ELISA and enzyme activity assays were used to examine the degree of Aβ deposition in the brains of Tg2576 mice. The Morris water maze task was analyzed using two-way ANOVA with repeated measures. Otherwise were analyzed by one-way ANOVA followed by Dunnett’s post hoc test.

Results: Treatment of HPB242 (5 mg/kg for 1 month) significantly attenuated cognitive impairments in Tg2576 transgenic mice. HPB242 also prevented amyloidogenesis in Tg2576 transgenic mice brains. This can be evidenced by Aβ accumulation, BACE1, APP and C99 expression and β-secretase activity. In addition, HPB242 suppresses the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as activation of astrocytes and microglial cells. Furthermore, activation of nuclear factor-kappaB (NF-κB) and signal transducer and activator of transcription 1/3 (STAT1/3) in the brain was potently inhibited by HPB242.

Conclusions: Thus, these results suggest that HPB242 might be useful to intervene in development or progression of neurodegeneration in AD through its anti-inflammatory and anti-amyloidogenic effects.

Keywords: Alzheimer’s disease, Amyloid-beta, NF-κB, STAT1/3, 2,4-bis(p-hydroxyphenyl)-2-butenal
upregulate mRNA and protein levels and enzymatic activity of β-secretase, a key enzyme in the production of Aβ [9,10].

Astrocytes and microglia are the major type of glial cells in the central nervous system and activation of these cells are involved in all types of neurodegenerative processes, indicating prominent remodeling in AD [11,12]. Activated astrocytes expressing glial fibrillary acidic protein (GFAP) are closely associated with AD pathology, such as Tau tangles, neuritic plaques and amyloid deposits [13]. Furthermore, astrocytes with increased beta-secretase 1 (BACE1) expression have been found in the brain in AD [14]. Fibrillar Aβ can activate microglia, resulting in production of toxic and inflammatory mediators like hydrogen peroxide, nitric oxide, and cytokines [15]. Microglial cells are closely associated with nearly all compact deposits of the Aβ-protein found in the senile plaques of AD [16]. Microglial activation is also involved in neuroprotection in the early phase, but, subsequently, extensive and continuous activation of microglia results in the neuroinflammation and Aβ accumulation in AD pathology [17].

Nuclear factor-kappa B (NF-kB) is a redox transcription factor that is critical for regulation of inflammation and various autoimmune diseases [12]. NF-kB is localized in the cytoplasm by the inhibitor of kB (IκB). After IκB is phosphorylated and degraded, NF-kB is released and translocated from the cytosol to the nucleus, and binds to its cognate DNA binding sites leading to expression of inflammatory mediators [18]. Expression of genes for inflammatory elements such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as cytokines, can be regulated by activation of NF-kB [10]. NF-kB activation was also found to promote neuronal resistance to Aβ toxicity [19]. NF-kB signaling increases BACE1 expression [20] and NF-kB inhibitors decrease Aβ production and β-secretase activity [21]. Recently, it was reported that inhibition of the NF-kB pathway could enhance α-secretases, but inhibit β-secretase activity, and thereby reduce the formation of Aβ [22]. Signal transducer and activator of transcription (STAT)1 and STAT3 are also significant regulators of neuroinflammation, Aβ generation [23] and cytokine-driven NF-kB-mediated Aβ gene expression [24]. It was reported that resveratrol prevented the pro-inflammatory properties of fibrillar Aβ on macrophages by potently inhibiting the effect of Aβ on IκB phosphorylation, STAT1 and STAT3 activation [25]. Endogenous BACE1 levels were decreased by overexpression of suppressor of cytokine signaling (SOCS), an endogenous negative regulator of STAT1 signaling [26], demonstrating that downregulation of STAT1 signaling suppresses BACE1 expression and Aβ generation in neurons [27]. STAT3 is another transcription factor that is typically associated with cytokine signaling during neuronal differentiation and inflammation [28]. The STAT3 pathway is disrupted in neurodegeneration induced by amyloid-peptide [29]. The STAT3-mediated transcriptional control of BACE1 leads to amyloidogenic processing of APP and Aβ generation [23].

The Maillard reaction (MR) products such as glucose-tyrosine and xylose-arginine have antioxidant, antimutagenic, and antibacterial effects [30-32]. Our previous studies have shown the fructose-tyrosine MR product, HPB242, inhibits lipopolysaccharide (LPS)-elevated Aβ levels in cultured astrocytes and microglial BV-2 cells through attenuation of LPS-induced neuroinflammatory reactions [10]. Therefore, in the present study, we investigated whether HPB242 improves memory function and inhibits amyloidogenesis via the prevention of neuroinflammation in Tg2576 mice.

**Methods**

**Animals**

In the present study we used Tg2576 mice as a model of AD. These mice overexpress human APP with the Swedish double mutations (K670N, M671L) under the control of a hamster prion protein promoter [33]. The 12-month-old Tg2576 female mice used in the present study were purchased from Taconic Farms (Germantown, NY, USA) and were maintained and handled in accordance with a protocol approved by the Institutional Animal Care and Use Committee of Laboratory Animal Research Centre at Chungbuk National University (Approval no. CBNU-144-1001-01).

**Chemicals**

Characterization of HPB242 has been described elsewhere [34]. In brief, we prepared 100 ml of fructose-tyrosine mixture including 0.1 M tyrosine and 0.05 M fructose. MR was carried out in temperature-controlled autoclave apparatus (Jisico, Seoul, South Korea) at 130°C for 2 hr. After 2 hr heating, the reaction mixture was filtered through a 0.45 μm membrane and used to isolate the active compounds through several fractionation steps. Fructose-tyrosine MR products were purified using a series of solvent fractionations; ethyl acetate (EtOAc), n-butanol, and water. The EtOAc fraction was subjected to silica gel column chromatography and eluted with increasing concentrations of methanol (MeOH) in dichloromethane (DCM). An A2 fraction via DCM: MeOH (20:1, v:v) of a first silica gel chromatography was separated to 23 sub-fractions via a second silica gel chromatography. Fractions B14 and B15 from the 23 sub-fractions were further purified by semi-preparative high performance liquid chromatography with a C18 column. The structure is shown in Figure 1A. Then 2,4-Bis...
(p-hydroxyphenyl)-2-butenal was given to Tg2576 mice (n = 8 in each group) in drinking water at the dose of 5 mg/kg for 1 month. (Figure 1B).

Morris water maze test

The Morris water maze test is a widely accepted method for examining cognitive function and was used in the present study as described previously [35]. Briefly, a circular plastic pool (height 35 cm, diameter 100 cm) was filled with water (plus white dye) maintained at 22 to 25°C. An escape platform (height 14.5 cm, diameter 4.5 cm) was submerged 0.5 to 1 cm below the surface of the water. The test was performed three times a day for 7 days during the acquisition phase (days 1 to 7), with three randomized starting points. The position of the escape platform was kept constant. Each trial lasted for 60 s or ended as soon as the mice reached the submerged platform. The swimming pattern of each mouse was monitored and recorded by a camera mounted above the center of the pool, and then memory tests were conducted.

Probe test

To assess memory consolidation, a probe test was performed 48 hr after the water maze test (on day 9). For the probe test, the platform was removed from the pool and the mice were allowed to swim freely. The swimming pattern of each mouse was monitored and recorded for 60s using the SMART-LD program (Panlab). Consolidated spatial memory was estimated by the time spent in the target quadrant area.

Passive avoidance test

The passive avoidance response was determined using step-through apparatus (Med Associates, Georgia, VT, USA). At 48 hr after the probe test (on day 11), a training trial was performed. To this end, each mouse was placed in the illuminated compartment of the apparatus facing away from the dark compartment. When the mouse moved completely into the dark compartment, it received an electric shock (0.45 mA, 3s duration). At 24 hr after the training trial (on day 12), each mouse was placed in the illuminated compartment and the latency period until it entered the dark compartment was determined and defined as the step-through latency. The cut-off time for the examination was 180s.

Collection and preservation of brain tissues

At 48 hr after the passive avoidance test, mice were anesthetized with diethyl ether and then perfused with PBS. The brains were immediately removed from skull, and the cortex and hippocampus were dissected on ice. All brain tissues were stored at −80°C until biochemical analysis.

Immunohistochemical staining

After being anesthetized with diethyl ether, subgroups of mice were perfused intracardially with 50 mL saline. The brains were removed from the skull and post-fixed in 4% paraformaldehyde for 24 h at 4°C. The brains were transferred to 30% sucrose solutions. Subsequently, brains were cut into 30 μm sections by using cryostat microtome (Leica CM1850; Leica Microsystems, Seoul, Korea). After multiple washing in PBS, endogenous peroxidase activity was quenched by incubation of the samples in 3% hydrogen peroxide in PBS for 30 minutes, followed by a 10-minutes wash in PBS. Sections were then incubated for 2 h at room temperature with a mouse polyclonal antibody against Aβ (1:5000; Covance, Berkeley, CA, USA), a rabbit polyclonal antibody against GFAP and iNOS (1:1000; Abcam, Inc, Cambridge, MA, USA), a rabbit polyclonal antibody against COX-2 (1:1000; Cayman, Ann Arbor, MI, USA) and a rabbit polyclonal antibody against ionized calcium binding adaptor molecule 1 (Iba1) (1:1000; Wako, Osaka, Japan). After incubation with the primary antibodies, sections were washed in PBS before being incubated for 1 h at room temperature in the presence of biotinylated goat anti-rabbit or anti-mouse IgG secondary antibodies (1:1000; Vector Laboratories,
Burlingame, CA, USA). Sections were then washed with PBS and incubated with avidin-peroxidase complex (Vector Laboratories) for 30 minutes before the immunocomplex was visualized using the chromogen 3,3'-diaminobenzidine (Vector Laboratories). Sections were then counterstained with hematoxylin. Finally, sections were dehydrated in ethanol, cleared in xylene and covered with Permount (n = 8 mice per group).

**Immunofluorescence staining**

The brain-tissue processing methods were the same as described above (Immunohistochemical staining). The mouse brain sections were incubated for 2 h at room temperature with a goat polyclonal antibody against p50 (1:500, Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA), a rabbit monoclonal antibodies against Iba1 (1:1000; Wako, Osaka, Japan) and a rabbit monoclonal antibodies against GFAP (1:1000; Abcam). After washing with PBS, the brain sections were incubated with an anti-rabbit or anti-mouse secondary antibody labeled with Alexa-Fluor 488 and Alexa-Fluor 568 (1:800 (all diluted 1:500, Santa Cruz Biotechnologies) and anti-β-actin (1:2500; Sigma). Blots were then incubated at room temperature for 2 h with corresponding peroxidase-conjugated anti-mouse or anti-rabbit antibodies (1/2000; Santa Cruz). Immunoreactive proteins were detected using an enhanced chemiluminescence (ECL) western blotting detection system. The relative density of the protein bands was scanned by densitometry using MyImage (SLB, Seoul, Korea) and quantified by Labworks 4.0 software (UVP Inc.).

**Western blot analysis**

Western blot analysis was performed with the hippocampus or cortex dissected and stored at −80°C. The brain tissues were homogenized with lysis buffer (PRO-PREP; iNtRON, Sungnam, Korea; n = 8 mice per group) and centrifuged at 2500 × g for 15 minutes at 4°C. Equal amounts of total protein (40 μg) isolated from brain tissues were resolved on 8% or 10% sodium dodecyl sulphate polyacrylamide gels and then transferred to nitrocellulose membranes (Hybond ECL; Amersham Pharmacia Biotech, Piscataway, NJ, USA). Membranes were incubated at room temperature for 2 h with the following specific antibodies: anti-BACE1 (1:500; Sigma, St Louis, MO, USA), anti-APP (1:500; Sigma), anti-iNOS, anti-GFAP (both 1:1000; Abcam), anti-Iba1 (1:1000; Wako), anti-COX-2 (1:1000; Cayman), anti-p50, anti-p65, anti-1xB, anti-p-1xB, anti-STAT1/3, anti-p-STAT1/3 (all diluted 1:500, Santa Cruz Biotechnologies) and anti-β-actin (1:2500; Sigma). Blots were then incubated at room temperature for 2 h with corresponding peroxidase-conjugated anti-mouse or anti-rabbit antibodies (1/2000; Santa Cruz). Immunoreactive proteins were detected using an enhanced chemiluminescence (ECL) western blotting detection system. The relative density of the protein bands was scanned densitometrically using My Image (SLB, Seoul, Korea) and quantified by Lab Works 4.0 (UVP, Upland, CA, USA).

**Gel electromobility shift assay (EMSA)**

Gel shift assays were performed according to the manufacturer’s recommendations (Promega, Madison, WI, USA). Briefly, brain tissues (100 mg) were suspended in 200 μl of solution A (1 M HEPES (pH 7.9), 0.15 M MgCl₂, 1 M KCl, 100 mM dithiothreitol, 0.5% Nonidet P-40, 0.1% Protease Inhibitor (Sigma), 0.1% Phosphatase Inhibitor (Sigma) and 100 mM phenylmethylsulfonyl fluoride). Tissues were then allowed to incubate on ice for 6 minutes and were centrifuged at 8000 rpm for 8 minutes. The pelleted nuclei were resuspended in solution C (solution A + (5 M NaCl, 20 mM ethylenediamine tetraacetic acid anticoagulant (EDTA), 20% glycerol)-(Nonidet P-40, 1 M KCl)) and allowed to incubate on ice for 20 minutes. The tissues were centrifuged at 15000 rpm for 15 minutes, and the resulting nuclear extract supernatant was collected in a chilled Eppendorf tube. Consensus oligonucleotides were endlabeled using T4 polynucleotide kinase and (γ-32P) ATP for 10 minutes at 37°C. Gel shift reactions were assembled and allowed to incubate at room temperature for 10 minutes followed by the addition of 1 μl (50,000 to 200,000 rpm) of 32P endlabeled oligonucleotide and another 20 minutes of incubation at 37°C. Subsequently 1.5 μl of gel loading buffer was added to each reaction and loaded onto a 6% non-denaturing gel, and electrophoresis was performed until the dye was four fifths of the way down the gel. The gel was dried at 80°C for 2 h and exposed to film overnight at −70°C. The relative density of the protein bands was scanned by densitometry using MyImage (SLB, Seoul, Korea), and quantified by Labworks 4.0 software (UVP Inc.).

**Measurement of Aβ_{1-42}**

A specific ELISA kit (Immuno-Biological Laboratories, Gunma, Japan) was used to determine Aβ(1 to 42) levels. Protein was extracted from brain tissue using lysis buffer containing protease inhibitors and centrifuged 2500 × g for 15 minutes at 4°C. The supernatant was collected. Briefly, 100 μL aliquots of brain tissue samples (total protein 100 μg) from eight mice in each group were added to pre-coated plates and incubated overnight at 4°C. After washing each well seven times with washing buffer, 100 μL chromogen-labeled antibody solution was added and the mixture was incubated for 1 h at 4°C in the dark. After washing each well nine times with washing buffer, 100 μL chromogen was added and the mixture was incubated for 30 minutes at room temperature in the dark. Finally, after added 100 μL stop solution, the resulting color was assayed at 450 nm using a microplate reader (Sunrise; TECAN, Mannedorf, Switzerland).

**Measurement of β-secretase**

β-secretase activity in Tg2576 mice brains was determined using a commercially available β-secretase activity
kit (Abcam). Protein was extracted from brain tissue using ice-cold extraction buffer, incubated on ice 20 minutes and centrifuged 10000 × g for 5 minutes at 4°C. The supernatant was collected. A total of 50 μL of sample (total protein 100 μg) was added to each well followed by 50 μL of 2 × reaction buffer and 2 μL of beta-secretase substrate incubated in the dark at 37°C for 2 hr. Fluorescence was read at excitation and emission wavelengths of 355 and 510 nm respectively, using a Fluostar Galaxy fluorimeter (BMG Lab Technologies, Offenburg, Germany) with Felix software (BMG Lab Technologies, Offenburg, Germany). Beta-secretase activity is proportional to the fluorimetric reaction, and is expressed as nmol/mg protein per minute.

Statistical analysis
All statistical analysis was performed with GraphPad Prism 4 software (Version 4.03; GraphPad software, Inc., San Diego, CA, USA). Group differences in the escape distance, latency, and velocity in the Morris water maze task were analyzed using two-way analysis of variance (ANOVA) with repeated measures, the factors being treatment and testing day. Otherwise, data were analyzed by one-way ANOVA followed by Dunnett’s post hoc test. All values are presented as mean ± standard error of the mean (SEM). Significance was set at $P < 0.05$ for all tests.

Results
Inhibition of memory impairment in Tg2576 mice by HPB242
To investigate the preventive effect of HPB242 against memory impairment and Aβ1–42 depositions in the AD model mice, we treated 12-month old Tg2576 transgenic mice with HPB242 for 1 month, and then compared memory deficiency with the non-treated mice using the water maze test. The Tg2576 mice were trained for three trials per day for 7 days. Escape latency and escape distances, which are the time and distance travelled to reach the platform in the water maze, were measured to determine the memory-improving effect of HPB242. The mice exhibited shorter time and shorter escape latency with the training, however, the escape latency of Tg2576 mice was not much reduced compared to the non-transgenic mice. Oral treatment with HPB242 (5 mg/kg) for 1 month significantly ameliorated memory dysfunction in the AD model mice. Statistical analysis of data from day 5 showed a significant memory-improving effect of HPB242 treatment. Escape latency ($F (1, 15) = 9.61, P < 0.05$ (treatment-wise)) ($F (6, 15) = 12.83, P < 0.05$ (day-wise)) of the treated group was shorter than that of the non-treated group (Figure 2A). Escape distance ($F (1, 15) = 10.31, P < 0.05$ (treatment-wise); $F (6, 15) = 5.51, P < 0.05$ (day-wise)) was also reduced by the treatment (Figure 2B). However, there was no significant difference in average speed between the non-treated and the HPB242-treated group (data not shown).

After the water maze test, we performed a probe test to analyze maintenance of memory. During the probe test, the time spent in the target quadrant by the Tg2576 mice group treated with HPB242 (18.78 ± 4.72 s) was significantly increased compared with the non-treated group (36.87 ± 8.14 s) ($F (1, 15) = 207.84, P < 0.05$) (Figure 2C). In particular, the time spent by HPB242-treated Tg2576 mice was similar to the time spent by non-transgenic mice (27.31 ± 10.73s).

We then evaluated learning and memory capacities by the passive avoidance test using the step-through method. In the passive avoidance test, there was no significant difference on the learning trial. However, in the test trial, Tg2576 mice treated with the HPB242 significantly increased the step-through latency (173.33 ± 36.56 s) compared with the non-treated transgenic mice (100.16 ± 32.49 s) ($F (1, 15) = 11.26, P < 0.05$) (Figure 2D).

Effect of HPB242 on Aβ accumulation and amyloidogenesis in brains of Tg2576 AD mice
Several studies reported that Aβ accumulation, which is thought to be a major cause of AD, occurred in the brain of Tg2576 mice. Hence, we investigated whether HPB242 attenuated Aβ accumulation in the brains of Tg2576 mice. Immunohistochemical analyses using Aβ1–42-specific antibodies revealed clearly the Aβ deposition in the cortex and hippocampus of non-treated Tg2576 mice. In contrast, there appeared to be reduced Aβ accumulation in the brains of HPB242-treated Tg2576 mice, as evidenced by a decrease in the number of Aβ plaques (Figure 3A). To determine whether the degree of Aβ deposition is paralleled with Aβ protein levels in the brain, quantitative analysis of Aβ1–42 levels was performed using an Aβ1–42-specific ELISA kit. As shown in Figure 3B, HPB242 treatment reduced Aβ1–42 levels in the brain of Tg2576 mice. In addition, to evaluate β-secretase activity (BACE1) we performed ELISA, and western blot analysis was performed to quantify β-secretase activity, APP and BACE1. ELISA analysis revealed that β-secretase activity was significantly reduced by treatment with HPB242 in the brain of Tg2576 mice (Figure 3C). Western blot analysis also revealed that APP, C99 and BACE1 levels were significantly decreased in both the cortex and hippocampus of HPB242-treated mice compared with non-treated mice (Figure 3D).

Effect of HPB242 on activation of astrocytes and microglia, and expression of iNOS and COX-2 in the Tg2576 mice brain
It has also been reported that activation of astrocytes and microglia is one of the characteristic features of AD; these can produce pro-inflammatory cytokines as
well as generate Aβ on activation. We thus examined activation of astrocytes and microglia in the brains of HPB242-treated and non-treated Tg2576 mice. In the results, GFAP-reactive cell number (activated astrocytes) and Iba1-reactive cell number (microglia) was reduced in the brains of HPB242-treated Tg2576 mice compared to those of non-treated Tg2576 mice (Figure 4A and B). To confirm these results, we investigated the expression of GFAP and Iba1 by western blot analysis. The results revealed that GFAP and Iba1 levels were significantly decreased in both the cortex and hippocampus of HPB242-treated compared with non-treated mice (Figure 4C). The analysis of NF-κB translocation on the Tg2576 mouse brain was performed by confocal microscopy. From confocal microscopy analysis, we found that HPB242 prevented NF-κB translocation from cytoplasm to nucleus in the microglia and astrocytes of the Tg2576 mouse brain (Figure 5A and B). Moreover, to confirm this detail, we also investigated the effects of HPB242 on NF-κB activation in Tg2576 mice. This DNA binding activity of NF-κB confirmed by EMSA analysis was inhibited by HPB242 (Figure 5C). The levels of cytoplasmic phosphorylated IkB, nuclear translocation of p50 and p65 were also inhibited by treatment with HPB242 (Figure 5D).

**Effect of HPB242 on NF-κB transcriptional and DNA binding in the brain of Tg2576 mice**

Since NF-κB is implicated for Aβ generation and neuroinflammatory reaction, we determined NF-κB DNA binding activity and expression of p50 and p65, subunits of NF-κB. The analysis of NF-κB translocation on the Tg2576 mouse brain was performed by confocal microscopy. From confocal microscopy analysis, we found that HPB242 prevented NF-κB translocation from cytoplasm to nucleus in the microglia and astrocytes of the Tg2576 mouse brain (Figure 5A and B). Moreover, to confirm this detail, we also investigated the effects of HPB242 on NF-κB activation in Tg2576 mice. This DNA binding activity of NF-κB confirmed by EMSA analysis was inhibited by HPB242 (Figure 5C). The levels of cytoplasmic phosphorylated IkB, nuclear translocation of p50 and p65 were also inhibited by treatment with HPB242 (Figure 5D).

**Effect of HPB242 on STAT1 and STAT3 activities**

In the nucleus, STATs and NF-κB regulate the activity of genes whose products are critical in controlling numerous
cellular and organismal processes, including inflammatory responses and Aβ deposition in the brain. We investigated whether HPB242 can prevent activation of STAT1 and STAT3 in the brain of Tg2576 mice. Our results showed that the DNA binding ability of STAT1 and STAT3 was inhibited by HPB242 performed by EMSA (Figure 6A). Western blot analysis revealed that p-STAT1 and p-STAT3 levels were significantly decreased in the whole brain of HPB242-treated Tg2576 mice compared with non-treated Tg2576 mice (Figure 6B).

**Discussion**

Accumulating epidemiological evidence has suggested that neuroinflammation may contribute to the occurrence and progression of AD [36-38]. The brains of patients with AD appear to display enhancement of hallmarks of neuroinflammation, including marked astrogliosis, and elevated release of proinflammatory mediators and cytokines, as well as microglial activation [6]. Indeed, neuroinflammation has been reported to cause amyloidogenesis in several AD animal models. For example,
Figure 4 HPB242 inhibited activation of astrocytes and microglia, and reduced expression of COX-2 and iNOS in the brains of Tg2576 mice. The effect of HPB242 on reactive astrocytes and activated microglia cells was measured by immunohistochemical analysis and western blotting analysis. The sections of mouse brain incubated with anti-glial fibrillary acidic protein (GFAP) (A) or ionized calcium binding adaptor molecule 1 (Iba1) (B) primary antibody and the biotinylated secondary antibody (n = 8). The stained tissues were viewed with a microscope (×100 or 400). Expression of GFAP and Iba1 were also examined by specific antibodies in the cortex and hippocampus (C). Each blot is representative for three experiments (n = 8). Inhibitory effects of HPB242 on the Tg2576 mice brain expression of inflammatory proteins. The sections of mouse brain incubated with anti-iNOS (D) or COX-2 (E) and the biotinylated secondary antibody (n=8). The resulting tissue was viewed with a microscope (×100 or 400). The expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were detected by western blotting using specific antibodies (F). Each blot is representative for three experiments (n = 8). *Significantly different to non-treated Tg2576 mice (P < 0.05).
APP/PS1 is an AD mouse model bearing mutant transgenes of APP and PS1; Aβ deposition and neuroinflammation were present in this mouse model in the early stage of life [39,40]. We also reported that Tg2576 mice displayed Aβ deposition, neuronal dysfunction, neuroinflammation and impairment of spatial memory by overexpression of APP [41]. Furthermore, neuroinflammatory reaction has been detected in Aβ-infused mice [42,43]. It was also reported that several anti-inflammatory compounds such as 4-O-methylhonokiol, thiacremonone and obovatol improved memory functions in AD animal models [6,12,42]. In the present study HPB242 inhibited memory impairment, and suppressed amyloidogenesis via its anti-neuroinflammatory properties in Tg2576 mice. These results indicated that anti-neuroinflammatory effects of HPB242 could be...
associated with anti-amyloidogenesis, and thus improve memory dysfunction.

BACE1 cleaves APP at the N-terminal position of Aβ [44]. It was reported that the Swedish mutant Tg2576 mice show enhanced cleavage of APP by increase of β-secretase activation [45]. It is known that Aβ is generated from APP by a series of proteolytic processes involving β- and γ-secretases in the amyloidogenic pathway [46]. In the present study, we found that HPB242 reduced Aβ accumulation in Tg2576 mice through inhibition of β-secretase activity and consecutive decrease in expression of APP and C99. Recently, it was also reported that the anti-inflammatory compound, thiacremone, a sulfur compound isolated from garlic, and 4-O-methylhonokiol effectively inhibited amyloidogenesis through reduced β-secretase activity in LPS-injected mice [12,47]. Activated astrocytes and microglia closely associate to amyloid plaques in AD. They could have a role in the neurotoxicity observed in AD because of the inflammatory reaction they generate [48]. BACE1 is induced in the proximity of activated astrocytes and microglia and upregulated in astrocytes and microglia upon exposure to pro-inflammatory cytokines influencing APP processing and β-secretase activity, to induce amyloidogenesis [49,50]. We found that the number of reactive astrocytes and microglia were elevated in the brain of Tg2576 mice, which was prevented by HPB242. HPB242 also demonstrated anti-inflammatory and anti-amyloidogenic effects in the Tg2576 mouse brain. Similar to these in vitro effects of HPB242-like anti-inflammatory and anti-amyloidogenic effects [10], it was also reported that BACE1 transcription is increased by other inflammatory gene expression such as iNOS and COX-2, which are regulated by NF-κB in reactive astrocytes and microglia [51]. In this study, we also found that HPB242 inhibits expression iNOS and COX-2, especially in the hippocampus of Tg2576 mice. Moreover, we found that the reactive cell number for GFAP and Iba1 are also reactive for p50, and the elevated co-reactive cell numbers in the Tg2576 mouse brain was reduced by HPB242. These results suggest that the inhibitory effect of HPB242 on the activation of astrocytes and microglia might be significant to modulate or halt neuroinflammatory-mediated amyloidogenesis.

NF-κB is a positive regulator in the expression of a variety of rapid-response genes involved in inflammatory effects and amyloidogenesis [52]. NF-κB activates the transcription of APP, BACE1 and some of the γ-secretase members and increases protein expressions and enzymatic activities, resulting in enhanced Aβ production [53]. We therefore investigated the activity of NF-κB as a possible mechanism of the anti-inflammatory and anti-amyloidogenesis effect of HPB242. In this study we showed that HPB242 reduced NF-κB activity in the Tg2576 mouse brain. In fact, in the previous in vitro studies, we found that HPB242 prevented LPS-induced neuroinflammation and amyloidogenesis in cultured astrocytes and microglia through inactivation of NF-κB [10]. In addition, numerous factors were reported to inhibit amyloidogenesis via suppression of NF-κB such as sorafenib [54], L-theanine [55] and tripchlorolide [56]. Further support comes from a previous study showing that in AD the brain...
contains increased levels of BACE1, C99 and NF-KB, and NF-KB expression leads to increase of BACE1 promoter activity and BACE1 transcription, while knockout of NF-KB decreases BACE1 gene expression in LPS-injected mice [6]. Moreover, in the present study, we also found that p50 and p65 subunits of NF-KB are translocated into the nucleus of astrocytes and microglia in the brains of Tg2576 mice, and then the translocation of p50 and p65 are inhibited by the treatment of HPB242. It was reported that Aβ activated the NF-KB pathway by selectively inducing the nuclear translocation of the p50 and p65 subunits, and promoted an apoptotic profile of gene expression [19]. Consistent with the effects on amyloidogenesis as well as C99 and BACE1 expression, NF-KB-induced increase in β-secretase activity was also prevented by HPB242. Therefore, inhibiting the effect of NF-KB could be significant in the anti-inflammatory and anti-amyloidogenic effect of HPB242.

STAT1/3 may also be activated in glial cells by a number of cytokines and then translocated from the cytosol to the nucleus [57]. In the nucleus, STAT1/3 regulate the activity of genes whose products are critical in controlling β-secretase activity [58]. STAT1/3 is transcriptionally activated by binding to the STAT1/3 binding sequence in the BACE1 promoter region; it is interesting to note that a number of transcription factor binding sites become activated in response to Aβ generation [45]. It has been reported that a humanin (HN) derivative named colivelin completely restored cognitive function in Tg2576 mice by activating the STAT3 [29]. In this study, we showed that HPB242 inhibited phosphorylation of STAT1/3 as well as DNA binding activity. In fact, in the previous studies we also found that blocking STAT3 abolished the inhibitory effect of HPB242 on NF-KB and amyloidogenesis induced by LPS [10]. Additionally, endogenous BACE1 levels were decreased by overexpression of SOCS, an endogenous negative regulator of STAT1 signaling [26], demonstrating that downregulation of STAT1 signaling suppresses BACE1 expression and Aβ generation in neurons [27]. These findings suggest that one mechanism by which HPB242 prevents anti-amyloidogenesis is due to a decrease in phosphorylation of STAT1 and STAT3. In conclusion, our data showed that HPB242 can protect Tg2576 mice from memory impairment through inhibition of NF-κB and STAT1/3, which could result in the inhibition of Aβ1-42 accumulation by attenuating β-secretase activity. We suggest that HPB242, a new product from a tyrosine-fructose MR, could be useful for treatment and/or prevention of neuroinflammatory diseases such as AD.

Abbreviations

AD: Alzheimer’s disease; Aβ: Amyloid-beta; ANOVA: Analysis of variance; APP: Amyloid precursor protein; BACE1: Beta-secretase 1; COX-2: cyclooxygenase-2; DCM: Dichloromethane; ECL: Enhanced chemiluminescence; EDTA: Ethylenediamine tetraacetic acid anticoagulant; EGCG: (−)-epigallocatechin-3-gallate; ELISA: Enzyme-linked immunosorbent assay; EMSA: Gel electromobility shift assay; EOAC: Ethyl acetate; GFRAP: Gliarial fibrillary acidic protein; HPB242: 2,4-bis(p-hydroxyphenyl)-2-butenal; Iba1: Ionized calcium binding adaptor molecule 1; kB: Inhibitor of κB; iNOS: Inducible nitric oxide synthase; LPS: Lipo polysaccharide; MR: Malillard reaction; MeOH: Methanol; NF-KB: Nuclear factor-kappa B; PBS: Phosphate-buffered saline; PS1: Presenilin1; SEM: Standard error of the mean; SOCS: Suppressor of cytokine signaling; STAT1/3: Signal transducer and activator of transcription 1/3.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

J-TH designed the study and prepared the manuscript. PJ and J-A K performed experiments. H-SJ isolated and characterized 2,4-bis(p-hydroxyphenyl)-2-butenal. D-YC and Y-JL discussed the study. All authors have read and approved the final version of this manuscript.

Acknowledgements

This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korean Government (MEST, MRC, 2011–0029480), by a grant (A101836) from the Korean Health Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea and by the Priority Research Centers Program through the NRF funded by the Ministry of Education, Science and Technology (2011–0031403).

Author details

1College of Pharmacy, Chungbuk National University, 12 Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Korea. 2Medical Research Center, Chungbuk National University, 12 Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Korea. 3College of Agriculture, Life and Environments Sciences, Chungbuk National University, 12 Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Korea. 4College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 712-749, Republic of Korea. 5School of Equine industries, Cheju Halla University, 38 Hallaehak-ro, Jeju 690-708, Korea.

Received: 19 September 2012 Accepted: 23 December 2012 Published: 5 January 2013

References

1. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of Aβ deposition in bicomice models of Alzheimer’s disease. Proc Natl Acad Sci USA 2011, 108:2528–2533.
2. Wang HY, Bakshi K, Frankfurter M, Stucky A, Goberdhan D, Shah BM, Burns LH. Reducing amyloid-related Alzheimer’s disease pathogenesis by a small molecule targeting filamin A. J Neurosci 2012, 32:9773–9784.
3. So PP, Zeldich E, Seyb R, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glickman MA, Abraham CR. Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-beta precursor protein dimerization. Ann J Neurodegener Dis 2012, 1:75–87.
4. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 2005, 37:289–305.
5. Drellana DI, Quintanilla RA, Maccioni RB. Neuroprotective effect of TNFα against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochem Biophys Acta 2007, 1773:254–263.
6. Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, Kim HM, Lee K, Cho WG, Jung JX, Han SB, Han JY, Nam SY, Yun YW, Jeong JH, Oh KW, Hong JT. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation 2012, 9:35.
7. Cho HJ, Kim SK, Jin SM, Hwang EM, Kim YS, Huh K, Mook-Jung I. IFN-γamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 2007, 55:253–262.
8. Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 2007, 184:69–91.
9. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23:9796–9804.

10. Lee YI, Choi DY, Choi IS, Han YJ, Jeong HS, Han SB, Oh KW, Hong JT. Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis (p-hydroxyphenyl)-2-butenal on amyloid-beta generation and inflammatory reactions via inhibition of NF-kappab and STAT3 activation in cultured astrocytes and microglial BV-2 cells. J Neuroinflammation 2011, 8:132.

11. Finnie JW, Blumbergs PC, Williamson MW. Alzheimer type II astrocytes in the brains of pigs with salt poisoning (water deprivation/ intoxication). Aust Vet J 2010, 88:405–407.

12. Lin GH, Lee YJ, Choi DY, Han SB, Jung JK, Hwang BY, Moon DC, Kim Y, Lee MK, Oh KW, Jeong HS, Leen YJ, Shin HK, Lee JH, Hong JT. Anti-amyloidogenic effect of thiacremone through anti-inflammation in vitro and in vivo models. J Alzheimers Dis 2012, 29:569–576.

13. Korolainen MA, Aurila S, Nyman TA, Alafuzoff I, Pirttila T. Proteomic analysis of glial fibrillary acidic protein in Alzheimer’s disease and aging brain. Neurobiol Dis 2005, 20:858–870.

14. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, Laferla FM, Struble RG, Rose GM, Patyno PR. Yan XX: BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer’s disease: differential Aβ antibody labeling of early-onset axonal terminal pathology. Neurotox Res 2013, 21:160–174.

15. Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC. Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation 2006, 3:24.

16. Stoehrmeier R, Kovelkovs PJ, Mastroeni D, Leonard B, Grover A, Rogers J. Microglial responses to amyloid beta peptide oposonation and indomethacin treatment. J Neuroinflammation 2005, 2:18.

17. Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haberl PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002, 16501–603.

18. Jin M, Suh SJ, Yang JH, Lu Y, Kim SJ, Kwon S, Jo TH, Kim JW, Park YI, Ahn GW, Lee CK, Kim CH, Son JK, Son KH, Chang HW. Anti-inflammatory activity of bark of Dioscorea batatas DECNCE through the inhibition of iNOS and COX-2 expressions in RAW264.7 cells via NF-kappab and ERK1/2 inactivation. Food Chem Toxicol 2010, 48:3073–3079.

19. Valerio A, Boroni F, Benarose M, Sarnia I, Ghisi V, Bresciani LG, Ferrario M, Bortolami F, Benarese M, Sarnico I, Ghisi V, Bresciani LG. Isolation and characterisation of an anti-inflammatory and in vivo model to Alzheimer's disease. J Alzheimers Dis 2012, 30:127–132.

20. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Vouskin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99–102.

21. Wang KG, Kim HY, Woo KS, Hong JT, Hwang BY, Jung JK, Lee J, Jeong HS: Isolation and characterisation of an α-glucosidase inhibitor substance from fructose–tyrosine Maillard reaction products. Food Chem 2011, 127:122–132.

22. Monir R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 1147–60.

23. Veehuis R. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 2011, 8:34–58.

24. McGeer EG, McGeer PL: Inflammatory processes in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:751–749.

25. Eikelboom P, Bate C, Van Gool WA, Hoezemans JJ, Rozemuller JM, Veehuis R, Williams A. Neuroinflammation in Alzheimer’s disease and prion disease. Glia 2002, 40:233–239.

26. Ruan L, Kang Z, Pei G, Le Y. Amyloid deposition and inflammation in APPsw/PS1dE9 mouse model of Alzheimer’s disease. Curr Alzheimer Res 2009, 6:531–540.

27. Pulli L, Pomeschik Y, Ols K, Malm T, Koistinah JO, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J Neuroinflammation 2012, 9:105.

28. Lee YI, Choi DY, Han SB, Kim YH, Kim KH, Hwang BY, Kang JK, Lee BJ, Oh KW, Hong JT. Inhibitory effect of ethanol extract of Magnolia officinalis on memory impairment and amyloidogenesis in a transgenic mouse model of Alzheimer’s disease via regulating beta-secretase activity. Phytother Res 2012, 26:645–650.

29. Choi DY, Lee JW, Peng J, Lee YJ, Han YJ, Lee CH, Choi IS, Han SB, Jung JK. Lee WS, Lee SH, Kwon BM, Oh KW, Hong JT. Obovatol improves cognitive functions in animal models for Alzheimer’s disease. J Neurochem 2012, 120:1048–1059.

30. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, Jung JK, Kim YH, Oh KW, Hong JT. 4-O-methylhydorxi attenuated beta-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. J Nutr Biochem 2011, 22:476–486.

31. Sastre M, Walter J, Gentleman SW. Interactions between APP secretes and inflammatory mediators. J Neuroinflammation 2008, 5:25.

32. Cole SL, Vassar R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007, 2:22.

33. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2013, 50:151–160.

34. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP(V717I) transgenic mice. J Neuroinflammation 2005, 2:22.
50. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T: Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007, 170:680–692.

51. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR: Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007, 85:1194–1204.

52. Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK: Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 2004, 18:1034–1036.

53. Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F: Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological abeta concentrations. J Biol Chem 2012, 287:24573–24584.

54. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, Arendash GW: Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009, 162:1220–1231.

55. Kim TJ, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW, Hong JT: L-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009, 47:1601–1610.

56. Pan XD, Chen XC, Zhu YG, Chen LM, Zhang J, Huang TW, Ye QY, Huang HP: Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 2009, 57:1227–1238.

57. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T: Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer’s disease brains. Neurosci Lett 1997, 237:17–20.

58. Fagerlund R, Melen K, Cao X, Julkunen I: NF-kappaB p52, RelB and c-Rel are transported into the nucleus via a subset of importin alpha molecules. Cell Signal 2008, 20:1442–1451.

doi:10.1186/1742-2094-10-2

Cite this article as: Jin et al.: Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer’s disease mice model. Journal of Neuroinflammation 2013 10:2.